Today, scientists still do not know the cause of Alzheimer’s disease (AD), yet decades of research advancements give hope to the possibility of slowing down early-onset of AD. Benfotiamine, a therapeutic drug that raises blood vitamin B1, levels very high, was recently tested as a pilot clinical study conducted by the Gibson Lab at the Burke Neurological Institute.
Stroke affects over 795,000 people in the U.S. alone each year, that is one person every 40 seconds. Dr. Tomoko Kitago, lab director of the Human Motor Recovery Laboratory at the Burke Neurological Institute, talks about stroke awareness, treatments and the importance of clinical trials.
The research team examined how myeloid cells can also facilitate repair by clearing debris and promoting tissue remodeling during the early stages of repair. The study showed that a transcription factor, hypoxia-inducible factor, which the Ratan lab has been studying for years, marks myeloid cells that are associated with good long term recovery.
Benfotiamine and Cognitive Decline in Alzheimer's Disease, a small exploratory clinical trial, conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute is listed in CNN Health’s article on ”Top 2020 health stories you may have missed because of Covid-19” under Advances in Alzheimer’s.
A small exploratory clinical trial conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute in collaboration with physicians at the Burke Rehabilitation Hospital, suggests that Benfotiamine is safe and potentially efficacious in improving cognitive outcomes among people living with Mild Cognitive Impairment and mild Alzheimer’s disease (AD).